Speculating in Takeover Targets Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets

ULBI 6.880

-0.7%

Nov 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: richardred who wrote (1646)	4/16/2007 1:00:09 PM
From: richardred	Read Replies (1) of 7242

SPPI-good sign, but more wait. CHICAGO, April 16 (Reuters) - Spectrum Pharmaceuticals Inc.(SPPI.O: Quote, Profile , Research) on Monday said its application for an experimental prostate cancer drug was given a priority review by U.S. regulators, triggering a $4 million payment to the company. The company said the U.S. Food and Drug Administration accepted the drug for an expedited review for satraplatin, a platinum-based oral drug for treating prostate cancer. The FDA is expected to make a decision by Aug. 15, 2007. yahoo.reuters.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next